BLTE Belite BIO (BLTE) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001889109
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
50
13F, latest reported quarter
What the filings say about BLTE
Insiders, 180 days
-$35.7M net sold
4 sellers · 50% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$39.9M
3 notices
Belite BIO insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BELITE BIO, INC insiders sold a net $35.7M of stock across 175 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 18, 2026.
- The trade is 1.4% of the 14,800 shares held after it.
- 2 other insiders sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Scholl Hendrik Peter sold about $32.7K of BLTE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 18, 2026.
- The trade is 0.2% of the 14,776 shares held after it.
- 2 other insiders sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Scholl Hendrik Peter sold about $4.0K of BLTE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 18, 2026.
- The trade is 0.8% of the 14,656 shares held after it.
- 2 other insiders sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Scholl Hendrik Peter sold about $19.9K of BLTE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 18, 2026.
- The trade is 0.3% of the 14,606 shares held after it.
- 2 other insiders sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Scholl Hendrik Peter sold about $8.3K of BLTE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 50 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jun 18, 2026.
- The trade is 0.5% of the 14,528 shares held after it.
- 2 other insiders sold within 30 days.
- 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Scholl Hendrik Peter sold about $13.1K of BLTE under a 10b5-1 plan on Oct 1, 2026; 2 other insiders sold within 30 days and 50 funds added in the latest 13F quarter.175 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$35.7M over 180 days
-$32.1M over 90 days
below 93% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
50 funds bought in last quarter
below 53% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.5% of the float short (float per yahoo 2026-10-27) · 7.1 days to cover · settled 2026-10-15
below 58% of Pharma & Biotech
What changed in the last 30 days
Oct 5Chief Medical Officer Scholl Hendrik Peter sold $82.7K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Officer Hendrik Peter Scholl filed to sell $679.3K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch BLTE
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+58.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BLTE: institutional holders (13F)
13F holdings, latest reported quarter
3,077,219 sh
$456.6M
1,232,877 sh
$189.8M
715,332 sh
$110.2M
494,564 sh
$76.2M
396,311 sh
$61.0M
Congress trades in BLTE
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BLTE planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Hendrik Peter Scholl
Filed 2026-10-01
$679.3K
Hao-Yuan Chuang
Filed 2026-08-12
$16.7M
Yu-Hsin Lin
Filed 2026-08-12
$22.5M
Dr. Hendrick P. Scholl
Filed 2026-06-18
$1.5M
BLTE mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ULTRACHINA PROFUND
$163.4K position · as of 2026-07-31
0.8%
Virtus Biotech Clinical Trials Etf
$356.9K position · as of 2026-07-31
0.8%
Eventide Healthcare & Life Sciences Fund
$9.6M position · as of 2026-06-30
0.5%
Even Herd Long Short ETF
$197.4K position · as of 2026-06-30
0.3%
EQ/T.Rowe Price Health Sciences Portfolio
$215.6K position · as of 2026-06-30
0.1%
T. Rowe Price Health Sciences Portfolio
$831.5K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 3
1 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $35.7M sold by insiders over 180 days, 50 funds added last quarter, $39.9M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BLTE financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$84.2M | -$40.0M | -$31.7M | -$12.8M |
| Net income | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| EPS (diluted) | -2.31 | -1.18 | -1.19 | -0.63 |
| Operating cash flow | -$37.0M | -$29.2M | -$29.8M | -$11.5M |
| Cash | $352.9M | $31.7M | $88.2M | $42.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
BLTE Stock Sonar score 3/7 axes
Find similar shapesCompareBLTE ranks highest on risk and compliance (52nd percentile) and institutional and government (47th), and lowest on insider conviction (11th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BLTE filings, in plain words
Are Belite BIO insiders buying or selling BLTE?
In the 180 days to 2026-10-28, Belite BIO insiders were net sellers, a net $35.7M across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of BLTE?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $39.9M of stock; the latest, by Hendrik Peter Scholl, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-28, Belite BIO insiders were net sellers of BLTE, a net $35.7M across purchases and sales reported on Form 4 by 4 sellers. 50% of the 92 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $39.9M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
